602 related articles for article (PubMed ID: 31445668)
1. Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy.
Hallaj S; Meshkini F; Chaleshtari MG; Ghorbani A; Namdar A; Soleimanpour H; Jadidi-Niaragh F
Cell Immunol; 2019 Nov; 345():103963. PubMed ID: 31445668
[TBL] [Abstract][Full Text] [Related]
2. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
3. Chimeric Antigen Receptor T Cell Immunotherapy for Tumor: A Review of Patent Literatures.
Fu M; Tang L
Recent Pat Anticancer Drug Discov; 2019; 14(1):60-69. PubMed ID: 30636615
[TBL] [Abstract][Full Text] [Related]
4. Targeting T cell malignancies using CAR-based immunotherapy: challenges and potential solutions.
Fleischer LC; Spencer HT; Raikar SS
J Hematol Oncol; 2019 Dec; 12(1):141. PubMed ID: 31884955
[TBL] [Abstract][Full Text] [Related]
5. Next-generation CAR T cells to overcome current drawbacks.
Lundh S; Maji S; Melenhorst JJ
Int J Hematol; 2021 Nov; 114(5):532-543. PubMed ID: 32594314
[TBL] [Abstract][Full Text] [Related]
6. Paving New Roads for CARs.
Hyrenius-Wittsten A; Roybal KT
Trends Cancer; 2019 Oct; 5(10):583-592. PubMed ID: 31706506
[TBL] [Abstract][Full Text] [Related]
7. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
Gauthier J; Yakoub-Agha I
Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
[TBL] [Abstract][Full Text] [Related]
8. Advances in Chimeric Antigen Receptor T-Cell Therapies for Solid Tumors.
Baybutt TR; Flickinger JC; Caparosa EM; Snook AE
Clin Pharmacol Ther; 2019 Jan; 105(1):71-78. PubMed ID: 30406956
[TBL] [Abstract][Full Text] [Related]
9. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
[TBL] [Abstract][Full Text] [Related]
10. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity.
Yu S; Yi M; Qin S; Wu K
Mol Cancer; 2019 Aug; 18(1):125. PubMed ID: 31429760
[TBL] [Abstract][Full Text] [Related]
11. Engineering CAR-T Cells for Next-Generation Cancer Therapy.
Hong M; Clubb JD; Chen YY
Cancer Cell; 2020 Oct; 38(4):473-488. PubMed ID: 32735779
[TBL] [Abstract][Full Text] [Related]
12. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
13. Risks and Benefits of Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Cancer: A Systematic Review and Meta-Analysis.
Grigor EJM; Fergusson D; Kekre N; Montroy J; Atkins H; Seftel MD; Daugaard M; Presseau J; Thavorn K; Hutton B; Holt RA; Lalu MM
Transfus Med Rev; 2019 Apr; 33(2):98-110. PubMed ID: 30948292
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy with CAR modified T cells in cancer: current landscape and future perspectives.
Coscia M; Vitale C; Cerrano M; Maffini E; Giaccone L; Boccadoro M; Bruno B
Front Biosci (Landmark Ed); 2019 Jun; 24(7):1284-1315. PubMed ID: 31136980
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
Brudno JN; Kochenderfer JN
Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance.
Boyiadzis MM; Dhodapkar MV; Brentjens RJ; Kochenderfer JN; Neelapu SS; Maus MV; Porter DL; Maloney DG; Grupp SA; Mackall CL; June CH; Bishop MR
J Immunother Cancer; 2018 Dec; 6(1):137. PubMed ID: 30514386
[TBL] [Abstract][Full Text] [Related]
17. CAR-T cells: the Chinese experience.
Wang L; Tan Su Yin E; Zhao H; Ni F; Hu Y; Huang H
Expert Opin Biol Ther; 2020 Nov; 20(11):1293-1308. PubMed ID: 32605454
[TBL] [Abstract][Full Text] [Related]
18. In Vitro-Transcribed mRNA Chimeric Antigen Receptor T Cell (IVT mRNA CAR T) Therapy in Hematologic and Solid Tumor Management: A Preclinical Update.
Soundara Rajan T; Gugliandolo A; Bramanti P; Mazzon E
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32899932
[TBL] [Abstract][Full Text] [Related]
19. CAR-T Cells for Cancer Treatment: Current Design and Next Frontiers.
Picanço-Castro V; Swiech K; Malmegrim KCR; Covas DT
Methods Mol Biol; 2020; 2086():1-10. PubMed ID: 31707664
[TBL] [Abstract][Full Text] [Related]
20. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
Han X; Wang Y; Wei J; Han W
J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]